Form 8-K - Current report:
SEC Accession No. 0001140361-23-053659
Filing Date
2023-11-16
Accepted
2023-11-16 16:16:20
Documents
13
Period of Report
2023-11-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20014811_8k.htm   iXBRL 8-K 29438
2 EXHIBIT 10.1 ef20014811_ex10-1.htm EX-10.1 236719
  Complete submission text file 0001140361-23-053659.txt   456160

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20231114.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20231114_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20231114_pre.xml EX-101.PRE 16044
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20014811_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 231414797
SIC: 2834 Pharmaceutical Preparations